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Breast cancer is the most common malignancy and the 
leading cause of cancer-related death in women world-
wide [1]. Whereas localized disease is largely curable, 
metastatic or recurrent disease carries a dismal prog-
nosis. Th  e tumor microenvironment is now recognized 
as an important participant of tumor progression and 
response to treatment. As a result, there is increasing 
interest in developing novel therapies targeting the 
microenvironment, particularly as it relates to invasive 
and metastatic progression.
Th   e normal breast duct consists of a luminal epithelial 
cell layer surrounded by myoepithelial cells, which 
produce and attach to the basement membrane. Th  e 
breast microenvironment is composed of extracellular 
matrix (ECM) and numerous stromal cell types, including 
endo  thelial and immune cells, ﬁ  broblasts, and adipocytes 
(Figure  1). Early work investigating epithelial-mesen-
chymal interactions in tissue diﬀ  erentiation  demon-
strated that embryonic mesenchyme strongly inﬂ  uences 
the terminal diﬀ  erentiation of both embryonic and adult 
epithelia [2]. Th  e inﬂ  uence of ECM is also observed in 
cell culture whereby normal mammary epithelial c  ells in 
laminin-rich three-dimensional matrix form acini with a 
central lumen, become responsive to lactogenic 
hormones, and are capable of producing milk proteins 
[3,4]. Components of the microenvironment, including 
macrophages, myoepithelial and endothelial cells, and 
several ECM molecules, have been shown to play critical 
roles in mammary duct morphogenesis [5]. Similarly, the 
tumor microenvironment is increasingly recognized as a 
major regulator of carcinogenesis [6]. For decades, 
pathologists have appreciated the wound-like appearance 
of desmoplastic tumors, including some breast carci  no-
mas. Th   e now-famous assessment by Dvorak that ‘tumors 
are wounds that do not heal’ is being redeﬁ  ned at the 
molecular level as the role of the tumor micro  environ-
ment in cancer progression is elucidated [7].
Breast tumors evolve via sequential progression through 
deﬁ  ned stages, starting with epithelial hyperproliferation 
and progressing to in situ, invasive, and metastatic 
carcino  mas [8]. Both clinical and experimental data 
suggest that ductal carcinoma in situ (DCIS) is a 
precursor of invasive ductal carcinoma (IDC; Figure 2A,B) 
[9,10]. DCIS lesions contain proliferating neoplastic cells 
conﬁ  ned to the duct (Figures 1B and 2). A critical, but 
poorly understood, step in breast cancer progression is 
the transition from in situ to invasive ductal carcinoma, 
which is deﬁ  ned by the loss of myoepithelial cell layer 
and basement membrane (Figure  2). Th  e subsequent 
spread of tumor cells to distant sites results in metastatic 
disease. Importantly, the tumor microenvironment has 
been implicated in each of these steps of cancer 
progression.
Comprehensive molecular profi  ling of the 
microenvironment during tumor progression
In a pioneering study, Allinen and colleagues [11] isolated 
multiple cell types from normal breast, DCIS and IDC 
lesions and analyzed their gene expression proﬁ  les using 
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© 2011 BioMed Central Ltdserial analysis of gene expression (SAGE). In addition, 
genetic changes were detected by cDNA array compre-
hensive genomic hybridization and single nucleotide 
poly  morphism arrays. Th   e results of this study 
demon  strated altered gene expression patterns in each 
cell type analyzed during breast cancer progression. 
Myoepithelial cells from normal breast tissue and DCIS 
had the highest number of diﬀ  erentially expressed genes. 
Figure 1. Alterations of the microenvironment from normal duct to in situ transition. (A) Schematic (transverse) view of a normal breast duct 
composed of a layer of luminal epithelial cells encircled by myoepithelial cells (green) and surrounded by a continuous basement membrane. 
Stroma containing fi  broblasts, immune cells, and vasculature surrounded by the extracellular matrix maintains the normal tissue structure. 
(B) Longitudinal view of the normal duct and in situ carcinoma. In ductal carcinoma in situ (DCIS), epigenetically and phenotypically altered 
myoepithelial cells (shown as brown cells) are surrounded by a still largely continuous basement membrane. Altered myoepithelial cells in DCIS are 
unable to aid polarization and organize the structure of the normal duct. At the same time in the stroma, the numbers of fi  broblasts and infi  ltrated 
leukocytes are increased and angiogenesis is enhanced. Cancer-associated fi  broblasts (shown as yellow-green fi  broblasts) and infi  ltrated leukocytes 
elevate secretion of growth factors, cytokines, chemokines, and matrix metalloproteinases (MMPs) to promote tumor progression. Potential cross-
talk between cell-cell and cell-matrix interactions are aberrantly regulated by both autocrine and paracrine networks of proteolytic enzymes, 
cytokines, and chemokines (red arrows; not all possible interactions are indicated). Interactions between stromal and cancer cells may interact with 
each other via paracrine signaling rather than direct cell-cell contact.
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Page 2 of 11A signiﬁ  cant fraction of these encode secreted proteins, 
suggest  ing the activation of aberrant autocrine and 
paracrine regulatory loops. Many of the genes involved in 
normal myo  epithelial cell diﬀ   erentiation and function 
were down  regulated in DCIS-associated myoepithelial 
cells, including those encoding laminin and oxytocin 
receptor, whereas genes that promote tumorigenesis 
were increased, including CXCL12 and CXCL14. Impor-
tantly, clonal genetic aberrations were only identiﬁ  ed 
within the malignant epithelium. Although some 
Figure 2. Alterations of the microenvironment in breast cancer progression from in situ to invasive carcinoma. (A) Schematic 
(transverse) view of the ductal carcinoma in situ (DCIS). Although the ducts are enclosed by the altered myoepithelial cells surrounded by the 
basement membrane, the multiple cell types of the stroma of DCIS have dramatically changed to create a favorable tumor microenvironment. 
(B) Longitudinal view of the duct from DCIS to invasive ductal carcinoma transition. Invasive ductal carcinoma (IDC) is defi  ned by degradation 
of the basement membrane, loss of myoepithelial cells, and invasion of epithelial cells into the stroma and vasculature. Tumor cells invade into 
the local environment due to the loss of the structural duct and autocrine/paracrine signaling that activated cell migration. The production of 
extracellular matrix-degrading proteases by the tumor cells and stromal cells is elevated during the in situ to invasive carcinoma transition, leading 
to destruction of the extracellular matrix such that the tumor cells can invade locally and release more secreted factors. Aberrantly secreted 
proteolytic enzymes, chemokines, and cytokines continue to attract leukocytes, modulate tumor remodeling, and increase tumor cell invasion to 
distant organs, eventually leading to metastasis.
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relevance of genetically abnormal stromal cells in human 
breast cancer, the majority of data support the hypothesis 
that gene expression and functional changes observed in 
the tumor microenvironment are not due to genetic 
alterations.
In a related study, Ma and colleagues [12] utilized laser 
capture microdissection and cDNA microarrays to 
analyze the gene expression proﬁ  les of patient-matched 
samples of normal- and tumor-associated epithelium 
(DCIS and IDC) and stroma. Again, the most dramatic 
gene expression changes both in the stromal and 
epithelial compartments were observed in the normal to 
DCIS transition. However, several ECM-degrading 
proteases, including matrix metalloproteinase (MMP)2 
and MMP14, showed elevated expression during in situ 
to invasive carcinoma transition, which may play a role in 
the destruction of the basement membrane. One 
limitation of this study is that the diﬀ  erent stromal cells 
were not individually isolated prior to analysis. Addition-
ally, laser capture microdissection is unable to separate 
luminal and myoepithelial cells and to fully isolate stroma 
from epithelium. In fact, the authors noted that the 
majority of genes with increased expression in IDC 
compared to DCIS epithelium were likely the result of 
stromal cell contamination.
Tumor-associated stromal cells maintain their altered 
phenotype in cell culture during prolonged passage [13], 
indicating hereditary changes such as epigenetic modiﬁ  -
ca  tions, as genetic alterations are very rarely detected 
[14]. Hu and colleagues [15] tested this hypothesis by 
analyzing the comprehensive DNA methylation patterns 
of multiple cell types from normal breast tissue, DCIS, 
and IDC using methylation-speciﬁ  c digital karyotyping. 
Signiﬁ    cant methylation changes were identiﬁ  ed in each 
cell type during tumor progression. Th   ese data imply that 
epigenetic modiﬁ  cations are at least in part responsible 
for the altered phenotype of cells composing the micro-
environment in breast cancer.
The importance of myoepithelial cells
Th   e key characteristic of invasive progression is the loss 
of the myoepithelial cell layer and basement membrane 
(Figure 2B). Studies utilizing both in vitro co-culture and 
xenograft models have demonstrated that normal 
myoepithelial cells inhibit tumor growth. To better 
characterize the role of myoepithelial and stromal cells in 
the transition from DCIS to IDC, Hu and colleagues [16] 
utilized the MCF10DCIS.com xenograft model, which 
forms DCIS-like lesions that spontaneously progress to 
IDC with histological and molecular characteristics 
resembling human lesions. Co-injection of normal myo-
epithelial cells eﬃ     ciently suppressed the growth of 
MCFDCIS xenografts and the transition to IDC whereas 
ﬁ  broblasts had tumor growth and progression-promoting 
eﬀ   ects. Gene expression proﬁ   ling and immuno  histo-
chemical analysis of luminal epithelial and myoepithelial 
cells from MCFDCIS xenografts and human breast 
tissues have identiﬁ   ed transforming growth factor β 
(TGFβ) and Hedgehog pathways as speciﬁ  cally expressed 
in myo  epithelial cells, implying an important role in these 
cells. Correlating with this, downregulation of TGFBR2, 
SMAD4, or GLI1 in MCFDCIS cells resulted in a 
decrease in myoepithelial cells and enhanced progression 
to invasion. Th  ese studies suggest that the loss of myo-
epithelial cells promotes DCIS to IDC transition. Th  e 
mechanism by which this loss occurs in human tumors is 
unclear. One hypothesis is that the diﬀ  erentiation  of 
myo  epithelial progenitors to fully diﬀ  erentiated  myo-
epithelial cells is compromised due to signals emitted by 
tumor epithelial and stromal cells. Th  e  identiﬁ  cation and 
characterization of these paracrine factors may lead to 
the development of novel therapeutic approaches for the 
prevention and treatment of invasive breast cancer.
Cancer-associated fi  broblasts
Normal ﬁ   broblasts maintain the extracellular environ-
ment through the production and remodeling of the 
ECM. Carcinoma-associated ﬁ   broblasts (CAFs) have 
distinct characteristics and substantial data support a 
role for CAFs in promoting tumor progression. CAFs are 
themselves heterogeneous, with a subset of them identi-
ﬁ  ed as myoﬁ  broblasts expressing alpha smooth muscle 
actin (αSMA), others expressing ﬁ  broblast  activation 
protein (FAP), desmin, S100A4 protein, and Th  y-1  [17].
Orimo and colleagues [13] demonstrated that CAFs 
promote tumor growth and increase tumor angiogenesis 
by secretion of stromal derived factor (SDF)-1/CXCL12, 
which acts in a paracrine fashion to increase tumor cell 
proliferation via CXCR4. Hepatocyte growth factor 
(HGF), acting through the c-Met receptor tyrosine 
kinase, is another CAF-derived factor that has been 
impli  cated in promoting tumor progression and meta-
stasis. Th   e paracrine activation of c-Met on tumor cells 
by HGF increases invasion of experimental DCIS lesions 
in xenografts [18]. Interestingly, co-culture of normal 
mammary ﬁ   broblasts with breast cancer cells can 
‘educate’ the ﬁ  broblasts to secrete HGF and increase their 
tumor-promoting activities [19].
Th  e origin of carcinoma-associated ﬁ  broblasts  has 
been actively investigated and multiple hypotheses have 
been proposed. One possibility is that they are derived 
from native interstitial ﬁ  broblasts whose phenotype has 
been modiﬁ   ed by persistent aberrant signaling from 
neighboring tumor epithelial cells. Alternatively, they can 
be diﬀ   erentiated from bone marrow-derived mesen-
chymal stem cells that are recruited to the tumor site via 
endocrine stimulation by tumor-derived factors. Th  is 
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marrow-derived cells within tumors from patients who 
have previously received gender mis-matched allogenic 
bone marrow transplantation [20], although the recruit-
ment of these cells by itself does not indicate functional 
relevance. However, a recent study demonstrated that 
certain xenografts ‘instigate’ the growth and metastasis of 
weakly tumorigenic cell lines via the activation and 
recruit  ment of bone marrow-derived cells [21]. In 
particu  lar, granulin-expressing bone marrow-derived 
cells stimulate both tumor progression and the desmo-
plastic response of resident ﬁ  broblasts. Th   ese data as well 
as data from other labs [22-25] support the hypothesis 
that tumor-derived signals stimulate the bone marrow to 
produce and emit cells that promote tumor progression. 
Th   us, targeting bone marrow-derived cells may inﬂ  uence 
the treatment of both localized and metastatic disease.
Matrix remodeling in tumor progression
Th  e ECM of breast cancers is markedly abnormal and 
believed to promote tumor progression. MMPs are a 
large family of endopeptidases, which are synthesized 
predominantly by ﬁ  broblasts and normally participate in 
tissue remodeling and wound healing. Besides degrading 
ECM components, MMPs can also activate chemokines, 
cytokines, adhesion molecules, and growth factors, 
which contribute to tumor progression by increasing 
tumor cell proliferation (such as the release of insulin-like 
growth factor from ECM by MMP3 and -7) or by 
promoting angiogenesis (for example, activation of 
angio  genic factors by MMP1, -2, -9, and -14) [26].
Abnormal physical characteristics of breast tumors, such 
as abnormal collagen cross-linking resulting in ECM 
stiﬀ   ening, also contribute to progression. Th  e forces 
generated by this stiﬀ  ening lead to enhanced integrin and 
growth factor signaling that promotes invasion. Lysyl 
oxidase, an amine oxidase commonly expressed in breast 
tumors, promotes collagen cross-linking and enhances 
ECM stiﬀ  ening and its inhibition increases tumor latency 
and decreases tumor burden in the MMTV-Neu model of 
breast cancer [27]. In addition, elevated expression of lysyl 
oxidase-like 2 is associated with worse prognosis in early 
stage estrogen receptor (ER)-negative breast cancers [28].
Leukocytes
Th  e link between inﬂ   ammation and cancer and the 
impor  tance of inﬁ  ltrating leukocytes in tumor develop-
ment are widely accepted, but the mechanisms mediating 
immune and tumor cell cross-talk are poorly understood. 
Immune cells are one of the most dynamic cell 
populations present within tumors and healing wounds 
and during the remodeling of breast tissue in pregnancy 
and involution [29,30]. During physiologic wound healing 
and breast tissue involution, immune responses are 
activated, but balanced towards the suppression of overt 
inﬂ  ammation, facilitating re-epithelialization and tissue 
healing [29,31].
High numbers of inﬁ  ltrating leukocytes are present in 
DCIS with focal myoepithelial cell layer disruptions [32], 
suggesting that they might play a role in invasive 
progression. Indeed, several groups have shown that 
tumor-associated macrophages (TAMs) facilitate angio-
genesis, ECM degradation, and tumor invasion through 
activation of epidermal growth factor receptor signaling, 
secretion of proteases and paracrine signaling between 
tumor cells [33,34]. Loss of macrophages in colony 
stimulating factor (CSF)-1 deﬁ  cient mice (Csf1op/op) had 
no eﬀ  ect on tumor initiation but dramati  cally reduced 
malignant progression [35]. To determine whether 
human breast cancer cells have similar response to 
macrophages, xenografts derived from human MCF-7 
cells in immunodeﬁ  cient mice were treated with either 
mouse CSF-1 antisense oligonucleotide or CSF-1 small 
interfering RNAs. Th   ese treatments suppressed mammary 
tumor growth by decreasing macrophage inﬁ  ltration, the 
production of MMPs and vascular endothelial growth 
factor (VEGF)-A, and endothelial cell proliferation [36]. 
Cumulatively, these functional studies in mouse models 
of breast cancer emphasize a prominent role for macro-
phages during breast cancer progression, and provide a 
plausible explanation for the association between TAMs 
and poor clinical prognosis.
Besides macrophages, other immune cells have also 
been implicated in breast cancer development. In a 
spontaneous mouse model of breast cancer the number 
of CD4+ regulatory T lymphocytes increased and systemic 
depletion of T cells using interleukin-2 immuno  toxin 
fusion protein inhibited tumor growth and maintained a 
strong and persistent anti-tumor immune response [37]. 
A recent study analyzed tumor-inﬁ  ltrating  CD8+ 
lympho  cytes in breast tumors and found that a higher 
frequency of these cells in stroma surrounding the tumor 
was associated with better patient survival [38]. Because 
these cells are required for cell-mediated immunity, these 
results may indicate an active anti-tumor immune 
response against breast tumors, the intensity of which 
may inﬂ  uence the risk of distant metastatic progression.
The microenvironment of metastases
Although detailed cellular and molecular characterization 
of the metastatic tumor microenvironment has not been 
performed, numerous functional studies support a role 
for tumor epithelial-stromal cell interactions. During 
metastatic progression, tumor cells encounter and must 
survive in a number of diﬀ  erent  microenvironments, 
such as blood, lymphatics, lymph nodes, and distant 
organs. Th  e  speciﬁ  c destination where the metastatic cell 
forms metastases may be mediated by the production of 
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of various products by the primary tumor that can create 
a favorable environment (Figure 3). Weinberg and 
colleagues [39] have shown that MDA-MB-231 xenograft 
tumors growing on one side of the mouse, termed 
instigator, mobilized bone marrow pre  cursors via 
secreting osteopontin to home to secondary metastatic 
sites, where they promoted the growth of a less malignant 
cell line. Despite the fact that the mechanism by which 
osteopontin supported metastasis is not clear, this study 
not only demonstrates the recruitment of bone marrow-
derived cells to metastatic sites but also highlights the 
systemic eﬀ  ects of primary tumor growth.
In animal models of breast cancer, F4/80+CSF-
1R+CD11b+Gr1-CX3CR1highCCR2high and VEGFR1high host 
macrophages, distinct from classical macrophages, are 
recruited to metastatic breast cancer cells extravasating 
in the lungs [40]. In another study, primary tumor-stimu-
lated macrophages increased the metastatic ability of 
tail-vein injected tumor cells via secretion of MMP9 and 
VEGF [41], although lung metastases only developed in 
mice bearing primary tumors, again indicating sys  temic 
eﬀ  ects of tumor growth.
A recent study provided another example of how 
paracrine signals emitted by stromal cells may play 
important roles in promoting breast cancer metastasis. 
Receptor activator of nuclear factor-κB (RANK) is highly 
expressed in human breast carcinoma cells, but the 
source of RANK ligand (RANKL) and its role in breast 
cancer metastasis was mostly unknown. In a mouse 
model of ERBB2-driven mammary tumors, Tan and 
colleagues [42] identiﬁ  ed a role for RANKL in the forma-
tion of lung metastases. Only CD4+ regulatory T cells in 
the stroma of mammary tumors produced RANKL, which 
stimulated RANK-expressing ERBB2-driven mammary 
tumors to metastasize. In addition, most RANKL+ T cells 
were located adjacent to myoﬁ  broblasts  expressing 
T-cell-attracting chemokine CCL5. Th   ese studies indicate 
the possibility that recruitment of distinct populations of 
leukocytes and stromal cells is required in the process of 
metastasis.
The prognostic relevance of microenvironmental 
changes
Interest in targeting the microenvironment comes not 
only from the identiﬁ   cation of ‘druggable’ targets 
(enzymes and receptors) but also from clinical data 
demonstrating that stroma-derived gene expression 
patterns predict clinical outcome. One of the ﬁ  rst such 
studies, by Wang and colleagues [43], ﬁ  rst deﬁ  ned an 
‘activated ﬁ  broblast’ gene expression signature that was 
then analyzed in genome-wide expression data of bulk 
breast tumor samples from patients with lymph node-
negative disease to determine if it has prognostic 
rele  vance. A 76-gene signature was identiﬁ  ed  that 
predicted shorter distant metastasis-free survival 
independent of patient age, tumor size, grade, or ER 
status. Th  e authors proposed that patients with smaller 
(<2 cm) tumors and good prognosis based on their 
signature may not beneﬁ  t from adjuvant chemotherapy 
and could be spared associated morbidities [43]. A 
related ﬁ  broblast signature was developed by Chang and 
colleagues [44], deﬁ  ned as ‘core serum response’ genes 
activated in ﬁ  broblasts exposed to serum. Many of the 
functions of the identiﬁ  ed genes were related to wound 
healing, such as matrix remodeling, myoﬁ  broblastic 
activation, cell proliferation and motility. Th  is gene 
signature was then validated as a predictor of clinical 
outcome when applied to expression proﬁ  ling of whole 
tumor samples [44,45].
More recently, investigators have focused on breast 
tumor stroma-derived gene expression changes. Finak 
and colleagues [46] analyzed gene expression changes 
within tumor stroma and identiﬁ  ed  ‘outcome-linked’ 
clusters that were independent of tumor grade, size, 
hormone receptor, and lymph node status. Th  e poor 
outcome cluster was associated with increased expression 
of hypoxia- and angiogenesis-related genes, whereas the 
good outcome cluster was enriched for T cell immune 
responses and natural killer cell markers. Th  e authors 
derived a 26-gene signature that predicted clinical out-
come independent of tumor ER or human epidermal 
growth factor receptor (HER)2 status, implying distinct 
stromal subtypes distinct of breast tumor subtype. In a 
related study, Farmer and colleagues [47] analyzed the 
gene expression proﬁ  les of reactive tumor stroma from 
biopsies obtained prior to treatment of ER-negative 
tumors and derived a signature that predicted clinical 
response to neoadjuvant chemotherapy. Similarly, 
Bergamaschi and colleagues [48] deﬁ  ned several ECM 
signatures based on gene expression proﬁ  ling of whole 
tumor samples that pre  dicted clinical response. In 
addition to these global proﬁ   ling studies, individual 
prognostic markers have also been identiﬁ  ed. In DCIS, 
patients with tumors expressing low levels of CD10 (a 
myoepithelial cell surface marker) had a higher risk of 
local relapse [49]. While potentially interesting, small 
sample size and mixing outcomes from patients treated 
with mastectomy or lumpectomy limit the validity of the 
ﬁ  ndings. Th   e expression of several CAF-derived proteins 
is also associated with clinical outcome. For example, 
high levels of platelet-derived growth factor-β receptor or 
SDF-1/CXCL12 and decreased caveolin-1 are associated 
with worse clinical outcome [50-52].
Therapeutic targeting of the microenvironment
New insights into the tumor microenvironment, both 
focused and global, are identifying novel therapeutic 
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Page 6 of 11Figure 3. Microenvironment in the metastasis process. Metastasis is a complicated multistep process that requires cancer cells to escape 
from the primary tumor, survive in the circulation, seed at distant sites and grow. Each step involves stromal cell and paracrine interactions of 
the microenvironment. Aberrantly secreted chemokines and cytokines from the primary tumor circulate into the blood stream, creating a pre-
metastatic niche even before tumor cell mobilization. Secreted factors functionally activate bone marrow-derived cells, which are then released 
into the circulation to subsequently incorporate these cells into distant organs, such as lung and liver, to create a favorable microenvironment 
for the cancer cell to be seeded. For the cancer cells to invade into the blood circulation, proteases are produced by bone marrow-derived cells, 
including macrophages and fi  broblasts. Following tumor cell intravasation, a series of steps is required for the establishment of secondary tumors in 
the metastatic sites. Disseminated cancer cells preferentially form metastases at sites where activated bone marrow-derived cells are localized and 
the primary tumor has created a favorable environment at the local organ. After seeding, persistent growth of the metastatic tumor requires the 
establishment of a vasculature that can be possibly achieved through the production of angiogenic growth factors.
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Page 7 of 11targets. Currently, three types of tumor microenviron-
ment-targeting therapies are in clinical practice: aroma-
tase inhibitors (which target the aromatase enzyme 
predominantly expressed by stromal components), 
angiogenesis-modulating agents (including anti-VEGF 
receptor antagonists), and inhibitors of HER family 
receptors (such as trastuzumab, which inhibits receptor 
signaling on epithelial cells triggered by stroma-produced 
growth factors).
Whereas aromatase inhibitors and trastuzumab have 
become standard therapy, the clinical eﬀ  ectiveness  of 
angiogenesis inhibitors is less clear [53]. In addition, 
there is a concern that inhibition of angiogenesis may 
enhance disease progression based on data in animal 
models where treatment with anti-angiogenic agents 
increased invasiveness and metastatic spread [54,55]. 
Potential selection for hypoxia-tolerant clones or establish-
ment of leaky, metastasis-promoting vessels could explain 
these results [56]. In addition to these concerns, 
bevacizumab, a clinically approved VEGF inhibitor, has 
been associated with signiﬁ   cant adverse reactions, 
including hemorrhage, neutropenia, gastrointestinal 
perfora  tion, and thromboembolic events. A recently 
published meta-analysis of 16 randomized controlled 
clinical trials administering bevacizumab demonstrated 
that this agent, when used in combination with chemo-
therapy, was associated with increased risk of fatal 
treatment-related adverse events compared to the use of 
chemotherapy alone [57]. Whereas targeting the tumor 
microenvironment is an exciting possibility, side eﬀ  ects 
resulting from disruption of homeostatic functions in 
normal tissues are very likely, as was demonstrated by the 
poor tolerability of MMP inhibitors. In the past years, 
numerous targets have been investigated in early clinical 
trials, including antibodies targeting FAP, c-Met antago-
nists and multi-targeted receptor tyrosine kinase inhibitors 
such as sunitinib [58,59]. Some of these have been 
plagued by poor side eﬀ  ect proﬁ  les whereas others have 
been well tolerated, but ineﬀ  ective.
In addition to drugs being developed against novel 
targets, the anti-tumor eﬀ   ects of several older agents 
seem to be mediated through microenvironmental actions. 
For example, bisphosphonates (e.g., zoledronic acid), 
which are used for the treatment of osteoporosis and the 
management of bone metastasis, are now recog  nized to 
have activity outside of the skeleton, including direct 
anti-tumor eﬀ   ects on the malignant epithelium, and 
modulating angiogenesis and immune cell inﬁ  ltration 
[60].
Osteoclasts are an important component of the normal 
bone microenvironment as well as bone metastases. 
Meta  static tumor cells secrete growth factors that 
activate osteoclasts, which degrade bone and release 
additional growth factors, triggering a paracrine cascade 
that promotes tumor growth and bone destruction. 
Denosumab is a monoclonal antibody that binds RANKL 
and inhibits osteoclast function. Recently, denosumab 
was compared to zoledronic acid in a phase III 
randomized clinical trial in breast cancer patients with 
bone metastases [61]. Th  e results of this trial demon-
strated that denosumab was well tolerated, and superior 
to zoledronic acid in delaying time to complications of 
bone metastases (that is, pathological fractures) but did 
not improve survival.
An important new hypothesis in targeting the tumor 
microenvironment is the induction of microenviron-
mental ‘reprogramming’. Rolny and colleagues [62] 
recently published an intriguing discovery that over-
expression of histidine-rich glycoprotein (HRG) in murine 
syngeneic tumor models induced ‘normalization’ of 
TAMs and blood vessel structure. Importantly, this was 
associated with decreased breast tumor growth and 
pulmonary metastasis, and increased sensitivity to 
chemotherapy. Th   e authors demonstrated that the eﬀ  ects 
of HRG were dependent on the presence of TAMs and in 
particular TAM conversion from the ‘M2’ pro-tumor/
pro-angiogenic phenotype to the ‘M1’ anti-tumor/pro-
inﬂ  ammatory phenotype. In addition, HRG expression 
was associated with vessel normalization, which was also 
dependent on TAM activity. Th  is study has linked the 
phenotypic switching of TAMs by HRG with orches-
tration of vascular normalization. Th  is  eﬀ  ect of HRG on 
TAMs seems to be mediated through the down-regula-
tion of placental growth factor, though the precise 
mecha  nism is unclear.
Coussens and colleagues have recently des  cribed that 
the ratio of macrophages to T cells predicts clinical 
outcome, with increased macrophage recruitment asso-
ciated with worse outcome [63]. Interestingly, cytotoxic 
chemotherapy induces the recruitment of TAMs into 
invasive carcinomas by increasing the expression of 
CSF-1, a macrophage-recruiting cytokine. Inhibition of 
TAM recruitment by several approaches increased the 
eﬃ   cacy of chemotherapy by decreasing tumor develop-
ment and metastasis in a CD8+ T cell-dependent manner. 
Th   e authors postulate that chemotherapy increases TAM 
recruitment that subsequently modulates T cells, favor-
ing the CD4+ T-cell phenotype, which leads to inhibition 
of anti-tumor immunity. Inhibition of TAMs promotes 
CD8+ T-cell recruitment and is associated with increased 
anti-tumor immunity. Th   ese data support the 
development of novel compounds that target TAMs and, 
in concert with cytotoxic chemotherapy, can encourage 
anti-tumor immunity [63].
Response to chemotherapy can be assessed by changes 
in tumor size and imaging characteristics as well as histo-
pathological assessment. Tumor growth can progress, 
stabilize or regress in response to chemotherapy. In the 
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shrinkage, it is possible that the tumor microenvironment 
actively participates in the tissue remodeling. A simplistic 
model would be that classic cytotoxic therapies kill tumor 
cells, which then gives stromal components the oppor-
tunity to ‘mop up’ the necrotic debris. An alternative 
hypothesis is that the microenvironment, either as a 
direct eﬀ  ect of chemotherapy or in response to signals 
derived from the assaulted epithelium, acquires an altered 
phenotype that independently inhibits tumor growth. 
Identiﬁ  cation of these microenvironmental changes that 
take place during tumor regression have not been inten-
sively studied. Such studies may identify ‘reprogramming’ 
events that can be pharmacologically mimicked with 
novel, non-cytotoxic agents. Such manipulation of the 
microenvironment to promote an anti-tumor phenotype 
in stromal components represents a novel treatment 
strategy.
Metronomic therapy refers to the frequent or con-
tinuous administration of low doses of chemotherapy 
with the goal of eliciting an anti-tumor response while 
minimizing side eﬀ  ects. Interestingly, metronomic thera-
pies have been implicated in inhibiting angiogenesis, 
promoting a beneﬁ   cial immune response and tumor 
dormancy [64]. Th  e mechanisms by which metronomic 
therapies inﬂ  uence these changes are largely unknown. 
One possible explanation is that these chronic therapies 
are re-modeling the epigenetic landscape of the tumor 
microenvironment. Just as the epigenetic changes 
identiﬁ  ed in tumors possibly arise from chronic exposure 
to pro-tumorigenic signals derived from malignant epi-
the  lium, one could postulate a similar aﬀ  ect from chronic 
exposure to anti-neoplastic agents.
Epigenetic therapies, such as the histone deacetylase 
inhibitor suberoylanilide hydroxamic acid (also called 
vorinostat), are currently under clinical investi  ga  tion for 
the treatment of breast cancer. While developed to target 
the malignant epithelium, their eﬀ   ect on the micro-
environment may induce alterations that help orchestrate 
an anti-tumor response. Currently, there are no reports 
of the gene expression or epigenetic proﬁ  les of tumor 
samples obtained from patients treated with metronomic 
therapy or histone deacetylase inhibitors. Th   ese data will 
be valuable to our understanding of the microenviron-
mental changes induced by these therapies.
Besides identifying new therapeutic targets, the micro-
environment has also been implicated in chemotherapy 
resistance. Weaver and colleagues [65], working with 
three-dimensional cultures, demonstrated that sensitivity 
to chemotherapy could be inﬂ  uenced by cellular polarity, 
which is mediated in part by integrin expression and 
exposure to basement membrane. Hiscox and colleagues 
[66] demonstrated that resistance to fulvestrant, an anti-
estrogen, promotes an invasive phenotype secondary to 
increased epithelial expression of c-MET, which is then 
activated by ﬁ   broblast-produced HGF. Loeﬀ  er  and 
colleagues [67] generated an oral vaccine against FAP and 
studied its eﬀ  ect on the growth of multidrug-resistant 
breast cancer in murine xenografts. Th   e vaccine decreased 
tumor collagen I, an ECM component previously impli-
cated in chemotherapy resistance, and tumors from these 
animals had a signiﬁ  cant improvement in chemotherapy 
uptake as well as decreased tumor growth resulting in 
increased survival. Th  ese data demonstrate that, in 
addition to promoting progression, the microenviron-
ment can modulate sensitivity or resistance to 
chemotherapy.
Conclusions and future directions and challenges
Breast cancer remains a major clinical challenge with 
considerable mortality as well as treatment-associated 
morbidity. Novel treatment strategies are urgently needed, 
especially in the setting of metastatic disease where 
outcomes are still dismal. Th  e breast cancer micro-
environ  ment is a complex mixture of cells, the proteins 
they secrete, and the ECM in which they reside. Altera-
tions within the microenvironment are now recognized 
during key steps of tumor progression, making them 
attractive candidates for therapeutic modulation. Th  e 
relative genomic stability of stromal cells makes the 
develop  ment of chemoresistance to stromal-target therapy 
less likely. Furthermore, the epigenetic modiﬁ  cations that 
contribute to phenotypic alterations, while inheritable, 
are reversible, and there is mounting interest in 
‘normalizing’ the altered stroma, thereby abrogating its 
tumor-supporting role.
One major obstacle facing stromal-targeted therapy is 
avoiding disruption of homeostatic function in normal 
tissues. Despite these challenges, our improved under-
standing of key aspects of tumor progression should lead 
to treatment strategies that can discriminate normal 
tissue from neoplasm.
How the tumor microenvironment changes during 
chemotherapy-induced tumor regression is still poorly 
understood. Insights into these changes may identify 
important pathways, which can be activated using non-
cytotoxic therapies. As the mainstay of aggressive forms 
of breast cancer will continue to rely heavily on cytotoxic 
therapies for the foreseeable future, agents without these 
characteristics will be particularly valuable in combi  na-
tion trials.
Translating our burgeoning knowledge of micro-
environ mental  inﬂ   uences on tumor progression into 
clinical practice is challenging. For example, targeting 
bone marrow-derived mesenchymal cells, which 
inﬂ  uence both primary tumor growth and the metastatic 
niche, prior to clinically evident metastatic disease makes 
intuitive sense. However, testing these potentially 
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refractory disease may not yield signiﬁ  cant improvements 
in such advanced disease. Th   oughtful clinical trial design, 
including neoadjuvant therapy during which pre- and 
post-treatment tumor samples can be analyzed, will be 
vitally important in developing stromal-targeted therapy. 
Despite these challenges, taken together, the majority of 
data support the rationale for targeting the tumor 
microenvironment in the treatment of breast cancer.
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